These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1238 related articles for article (PubMed ID: 35644823)

  • 21. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
    Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Various impacts of driver mutations on the PD-L1 expression of NSCLC.
    Chu CH; Huang YH; Lee PH; Hsu KH; Chen KC; Su KY; Yu SL; Tseng JS; Yang TY; Chang GC
    PLoS One; 2022; 17(8):e0273207. PubMed ID: 35980949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    Zheng Q; Huang Y; Zeng X; Chen X; Shao S; Jin Y; Xue Q; Wang Y; Guo Y; Gu B; Wu C; Li Y
    J Cancer Res Clin Oncol; 2021 May; 147(5):1547-1556. PubMed ID: 33196892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
    Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
    ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
    Yang H; Chen H; Luo S; Li L; Zhou S; Shen R; Lin H; Xie X
    Oncotarget; 2017 Apr; 8(14):23517-23528. PubMed ID: 28423587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.
    Liu Q; Huang Q; Yu Z; Wu H
    Clin Respir J; 2022 Mar; 16(3):216-225. PubMed ID: 35081265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
    Bylicki O; Tomasini P; Radj G; Guisier F; Monnet I; Ricordel C; Bigay-Game L; Geier M; Chouaid C; Daniel C; Swalduz A; Toffart AC; Doubre H; Peloni JM; Moreau D; Subtil F; Grellard JM; Castera M; Clarisse B; Martins-Lavinas PH; Decroisette C; Greillier L;
    Eur J Cancer; 2023 Apr; 183():38-48. PubMed ID: 36801605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
    Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
    Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
    BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
    Song Z; Su H; Zhang Y
    Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
    Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
    Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.